Kura Oncology Reports Q4 Earnings Miss

Biopharmaceutical company posts lower-than-expected revenue and wider loss per share.

Published on Mar. 5, 2026

Got story updates? Submit your updates here. ›

Kura Oncology Inc., a San Diego-based biopharmaceutical company, reported a loss of $81 million in its fourth quarter, or $0.92 per share, missing Wall Street expectations. The company also posted revenue of $17.3 million, falling short of analyst forecasts of $29.8 million.

Why it matters

Kura Oncology is a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer. The company's Q4 earnings miss and lower-than-expected revenue could raise concerns among investors about the company's financial performance and the progress of its drug development pipeline.

The details

In the fourth quarter, Kura Oncology reported a loss of $81 million, or $0.92 per share, compared to the average analyst estimate of a loss of $0.72 per share. The company's revenue for the quarter was $17.3 million, falling short of the $29.8 million expected by analysts. For the full year, Kura Oncology reported a loss of $278.7 million, or $3.18 per share, on revenue of $67.5 million.

  • Kura Oncology reported its Q4 and full-year 2025 earnings on March 5, 2026.

The players

Kura Oncology Inc.

A clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer.

Got photos? Submit your photos here. ›

The takeaway

Kura Oncology's Q4 earnings miss and lower-than-expected revenue could raise concerns about the company's financial performance and the progress of its drug development pipeline, which will be important factors for investors to monitor going forward.